LUMO - Lumos Pharma Inc Stock Price, Fair Value and News

2.55USD-0.08 (-3.04%)Delayed

Market Summary

USD2.55-0.08

Delayed

-3.04%

LUMO Stock Price

View Fullscreen

LUMO RSI Chart

LUMO Valuation

Market Cap

20.7M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

13.57

EV/EBITDA

0.07

Price/Free Cashflow

-0.59

LUMO Price/Sales (Trailing)

LUMO Profitability

EBT Margin

-2293.57%

Return on Equity

-212.91%

Return on Assets

-132.24%

Free Cashflow Yield

-168.1%

LUMO Fundamentals

LUMO Revenue

Revenue (TTM)

1.5M

Rev. Growth (Yr)

61.33%

Rev. Growth (Qtr)

11.7K%

LUMO Earnings

Earnings (TTM)

-37.1M

Earnings Growth (Yr)

-42.13%

Earnings Growth (Qtr)

-10.4%

Breaking Down LUMO Revenue

Last 7 days

-12.1%

Last 30 days

1.2%

Last 90 days

-13.8%

Trailing 12 Months

-25%

How does LUMO drawdown profile look like?

LUMO Financial Health

Current Ratio

6.24

LUMO Investor Care

Buy Backs (1Y)

0.66%

Diluted EPS (TTM)

-4.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.5M	0	0	0
2023	2.1M	2.2M	1.7M	2.1M
2022	553.3K	876.5K	1.2M	1.5M
2021	0	188.7K	209.3K	230.0K
2020	744.0K	552.0K	360.0K	168.0K
2019	9.6M	6.7M	3.8M	936.0K
2018	35.9M	27.7M	22.4M	12.5M
2017	32.8M	41.2M	31.3M	28.7M
2016	35.0M	29.6M	30.7M	35.8M
2015	191.8M	210.9M	230.1M	68.5M
2014	1.1M	1.1M	86.8M	172.6M
2013	1.5M	1.2M	1.1M	1.1M
2012	1.7M	1.8M	1.7M	1.7M
2011	2.0M	2.0M	1.9M	1.9M
2010	0	0	1.5M	2.1M
2009	0	0	0	934.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lumos Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 08, 2021	flynn james e	sold	-2,376,100	22.3083	-106,512	-
Jan 07, 2021	flynn james e	sold	-396,821	24.5376	-16,172	-
Jan 06, 2021	flynn james e	sold	-652,703	22.4768	-29,039	-

Which funds bought or sold LUMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-3,484	31,688	-%
May 15, 2024	Blackstone Inc.	reduced	-75.92	-816,715	221,720	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	37,467	37,467	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	-	-146,377	1,146,650	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-41.98	-71,170	77,953	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-130	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-8.92	-26,064	109,464	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	12.72	-36.00	89,958	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	70.97	2,584	7,589	-%

Are Funds Buying or Selling LUMO?

Are funds buying LUMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUMO

No. of Funds

Unveiling Lumos Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	goldman sachs group inc	5.1%	406,711	SC 13G/A
Feb 06, 2024	wells fargo & company/mn	5.3%	417,051	SC 13G
Nov 29, 2023	blackstone holdings ii l.p.	4.9%	385,683	SC 13D/A
Jun 20, 2023	farb daniel stuart	4.90%	4e+05	SC 13D/A
Jun 02, 2023	farb daniel stuart	6.08%	496,891	SC 13D/A
May 25, 2023	farb daniel stuart	7.87%	643,338	SC 13D/A
Feb 15, 2023	farb daniel stuart	9.07%	760,000	SC 13D
Feb 07, 2023	goldman sachs group inc	5.6%	469,402	SC 13G
Jan 24, 2023	farb daniel stuart	9.07%	760,000	SC 13G/A
Feb 02, 2022	farb daniel stuart	5.94%	496,811	SC 13G/A

Recent SEC filings of Lumos Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
Apr 22, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Lumos Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Lumos Pharma Inc News

Latest updates

Lumos Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-80.0%	165,000	826,000	7,000	527,000	691,000	512,000	497,000	403,000	111,000	93,250	75,500	57,750	40,000	74,000	33,000	233,000	433,000	246,000	151,000	176,500	202,000
Operating Expenses	1.8%	11,027,000	10,830,000	8,939,000	10,170,000	8,726,000	9,347,000	8,047,000	8,327,000	7,842,000	6,789,000	7,497,000	8,674,000	7,094,000	7,231,000	6,910,000	5,236,000	2,385,000	2,698,000	2,595,000	2,138,000	11,148,000
S&GA Expenses	-100.0%	-	4,173,000	3,893,000	4,146,000	4,357,000	4,485,000	3,918,000	3,682,000	3,621,000	3,428,000	3,385,000	4,561,000	4,631,000	5,156,000	4,147,000	3,331,000	1,254,000	1,496,000	714,000	683,000	5,426,000
R&D Expenses	8.9%	7,248,000	6,657,000	5,046,000	6,024,000	4,369,000	4,862,000	4,129,000	4,645,000	4,221,000	3,361,000	4,112,000	4,113,000	2,463,000	2,075,000	2,763,000	1,905,000	1,131,000	1,202,000	1,881,000	1,455,000	5,722,000
EBITDA Margin	-34.5%	-22.94	-17.05	-18.85	-14.50	-14.09	-19.45	-24.11	-34.54	-56.11	-134	-149	-130	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-37,000	-	-	-40,000	-	-	48,000	-	-	-	-	1,000
Income Taxes	-	-	-	-	-29,000	-	-13,000	-	-	-	-636,000	-	-	-14,000,000	-2,432,000	-1,426,000	-5,463,000	-	-	-	-	27,500
Earnings Before Taxes	100.0%	-	-9,457,000	-8,300,000	-8,960,000	-	-8,260,000	-7,251,000	-7,844,000	-	-6,277,000	-7,488,000	-8,670,000	-7,067,000	-667,000	-6,779,000	-5,123,000	-2,362,000	-2,669,000	-2,569,000	-2,105,000	-10,546,000
EBT Margin	-34.5%	-22.94	-17.05	-18.87	-14.51	-14.09	-19.46	-24.06	-34.55	-56.15	-135	-152	-132	-	-	-	-	-	-	-	-	-
Net Income	-10.4%	-10,441,000	-9,457,000	-8,300,000	-8,931,000	-7,346,000	-8,247,000	-7,251,000	-7,844,000	-7,720,000	-5,641,000	-7,488,000	-8,670,000	-2,415,000	1,765,000	-5,353,000	340,000	-8,271,000	-2,669,000	-2,569,000	-2,105,000	-10,569,000
Net Income Margin	-46.7%	-24.35	-16.59	-18.90	-14.27	-14.59	-20.40	-23.72	-32.74	-53.36	-132	-129	-95.15	-	-	-	-	-	-	-	-	-
Free Cashflow	-74.4%	-12,894,000	-7,393,000	-7,820,000	-6,685,000	-9,197,000	-5,826,000	-5,519,000	-7,245,000	-8,033,000	-5,811,000	-7,046,000	-6,379,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-30.9%	28.00	41.00	48.00	56.00	64.00	72.00	79.00	85.00	93.00	100	106	114	120	129	136	172	183	145	107	121	129
Current Assets	-31.2%	28.00	40.00	47.00	56.00	63.00	72.00	79.00	85.00	93.00	100	106	113	120	128	135	171	93.00	5.00	103	110	118
Cash Equivalents	-33.9%	23.00	35.00	36.00	38.00	44.00	56.00	74.00	80.00	87.00	95.00	101	108	114	99.00	106	73.00	86.00	5.00	8.00	10.00	12.00
Net PPE	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	3.00	3.00	4.00
Liabilities	-20.2%	11.00	13.00	12.00	13.00	11.00	13.00	12.00	11.00	11.00	11.00	12.00	13.00	11.00	12.00	18.00	56.00	61.00	41.00	20.00	22.00	22.00
Current Liabilities	-37.2%	4.00	7.00	6.00	7.00	5.00	7.00	5.00	5.00	5.00	5.00	6.00	7.00	5.00	6.00	7.00	43.00	47.00	1.00	14.00	9.00	9.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00
Shareholder's Equity	-36.1%	17.00	27.00	35.00	44.00	53.00	60.00	68.00	75.00	82.00	89.00	94.00	101	109	117	119	116	122	79.00	86.00	99.00	107
Retained Earnings	-6.5%	-172	-161	-152	-143	-134	-127	-119	-111	-104	-96.42	-90.78	-83.29	-74.62	-65.99	-63.58	-65.34	-59.99	-59.68	-325	-311	-301
Additional Paid-In Capital	0.3%	190	189	188	188	187	187	187	187	186	185	185	184	184	182	182	182	181	0.00	413	411	409
Shares Outstanding	0.1%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	22.00	-	-	-	46.00	-	-	-	63.00	-	-	-	95.00	-	-	-	43.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-74.4%	-12,894	-7,393	-7,820	-6,685	-9,197	-5,826	-5,519	-7,245	-8,033	-5,811	-7,046	-6,379	-10,412	-6,980	393	-13,100	-3,310	-2,733	-1,886	-2,285	-2,186
Share Based Compensation	10.7%	580	524	559	653	586	587	593	575	565	494	490	846	1,049	318	305	274	177	47.00	44.00	40.00	48.00
Cashflow From Investing	-83.8%	1,000	6,172	5,950	1,083	-2,463	-11,358	-	-	-	-30.00	-	-	26,000	-12.00	32,496	-14.00	84,179	-2.00	-	-	-
Cashflow From Financing	-100.7%	-5.00	742	-435	-574	-309	-475	-326	-2.00	-18.00	-	-	-26.00	-166	96.00	-11.00	-10.00	-	22.00	-	46.00	-46.00
Buy Backs	-	-	-	426	579	305	478	197	-	-	-	-	-	44.00	-	-	-	-	2.00	1.00	1.00	32.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LUMO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Royalty revenue	$ 165	$ 691
Total revenues	165	691
Operating expenses:
Research and development	7,248	4,369
General and administrative	3,779	4,357
Total operating expenses	11,027	8,726
Loss from operations	(10,862)	(8,035)
Other income and expense:
Other income, net	263	119
Interest income	158	570
Other income, net	421	689
Net loss	$ (10,441)	$ (7,346)
Net loss per share:
Basic (in dollars per share)	$ (1.29)	$ (0.89)
Diluted (in dollars per share)	$ (1.29)	$ (0.89)
Weighted average number of common shares outstanding:
Basic (in shares)	8,104,905	8,239,941
Diluted (in shares)	8,104,905	8,239,941
Other comprehensive income:
Unrealized gain on short-term investments	$ 0	$ 4
Total comprehensive loss	$ (10,441)	$ (7,342)

LUMO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 23,179	$ 35,078
Short-term investments	0	999
Prepaid expenses and other current assets	4,184	3,748
Other receivables	181	210
Total current assets	27,544	40,035
Non-current assets:
Right-of-use asset	534	603
Total assets	28,078	40,638
Current liabilities:
Accounts payable	569	890
Accrued expenses	3,552	5,858
Current portion of lease liability	293	282
Total current liabilities	4,414	7,030
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority	6,000	6,000
Lease liability	225	303
Total liabilities	10,639	13,333
Commitments and contingencies
Stockholders' equity:
Undesignated preferred stock, $0.01 par value: Authorized shares - 5,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 0 at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value: Authorized shares - 75,000,000 at March 31, 2024 and December 31, 2023; issued shares - 8,132,007 and 8,125,728 at March 31, 2024 and December 31, 2023, respectively, and outstanding shares - 8,107,121 and 8,102,555 at March 31, 2024 and December 31, 2023, respectively	81	81
Treasury stock, at cost, 24,886 and 23,173 shares at March 31, 2024 and December 31, 2023, respectively	(201)	(196)
Additional paid-in capital	189,517	188,937
Accumulated deficit	171,958	161,517
Total stockholders' equity	17,439	27,305
Total liabilities and stockholders' equity	$ 28,078	$ 40,638

About Lumos Pharma Inc

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

CEO	Mr. Richard J. Hawkins
WEBSITE	https://lumos-pharma.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Lumos Pharma Inc Frequently Asked Questions

What is the ticker symbol for Lumos Pharma Inc? What does LUMO stand for in stocks?

LUMO is the stock ticker symbol of Lumos Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lumos Pharma Inc (LUMO)?

As of Fri May 17 2024, market cap of Lumos Pharma Inc is 20.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUMO stock?

You can check LUMO's fair value in chart for subscribers.

What is the fair value of LUMO stock?

You can check LUMO's fair value in chart for subscribers. The fair value of Lumos Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lumos Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lumos Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LUMO is over valued or under valued. Whether Lumos Pharma Inc is cheap or expensive depends on the assumptions which impact Lumos Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUMO.

What is Lumos Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LUMO's PE ratio (Price to Earnings) is -0.56 and Price to Sales (PS) ratio is 13.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lumos Pharma Inc's stock?

In the past 10 years, Lumos Pharma Inc has provided -0.188 (multiply by 100 for percentage) rate of return.